Startseite>>Signaling Pathways>> Others>>Bencianol (ZY15051)

Bencianol (ZY15051)

Katalog-Nr.GC31028

Bencianol (ZY15051) ist ein halbsynthetisches Flavinoid mit krampflÖsender Wirkung.

Products are for research use only. Not for human use. We do not sell to patients.

Bencianol (ZY15051) Chemische Struktur

Cas No.: 85443-48-7

Größe Preis Lagerbestand Menge
1mg
92,00 $
Auf Lager
5mg
184,00 $
Auf Lager
10mg
313,00 $
Auf Lager
20mg
552,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Bencianol is a the semisynthetic flavinoid, with anti-spasmogenic activities.

Bencianol causes a dose-related (1-100 μg/mL) reversal of contractions induced by 5-hydroxytryptamine, nor-adrenaline, angiotensin II, prostaglandin F2a, and U-46619 (a thromboxane-A2 mimetic). Bencianol is more effective against contractions induced by EC50 compared to maximal concentrations of each agent, and is least effective against the thromboxane-A2 mimetic, U-46619[1]. Bencianol (0.1-100 nM) produces cytoprotective effects against CCl4 induced cell injury on the above three parameters[2].

[1]. Whalley ET, et al. Anti-spasmogenic effects of bencianol (ZY15051) on human cerebral arteries in vitro. Cephalalgia. 1985 Dec;5(4):217-21. [2]. Maignan MF, et al. Cytoprotective effects of Bencianol on porcine vascular endothelial cells in vitro. J Submicrosc Cytol. 1986 Jan;18(1):47-51.

Bewertungen

Review for Bencianol (ZY15051)

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Bencianol (ZY15051)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.